Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Gains from Sales and Divestitures (2022 - 2025)

Biodesix (BDSX) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $37000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures rose 23.33% year-over-year to $37000.0, compared with a TTM value of $37000.0 through Dec 2025, up 23.33%, and an annual FY2025 reading of $37000.0, up 23.33% over the prior year.
  • Gains from Sales and Divestitures was $37000.0 for Q4 2025 at Biodesix, up from $35000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $710000.0 in Q4 2023 and bottomed at $2000.0 in Q3 2024.
  • Average Gains from Sales and Divestitures over 4 years is $143333.3, with a median of $37000.0 recorded in 2025.
  • The sharpest move saw Gains from Sales and Divestitures tumbled 98.48% in 2024, then soared 1650.0% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $357000.0 in 2022, then surged by 98.88% to $710000.0 in 2023, then crashed by 95.77% to $30000.0 in 2024, then grew by 23.33% to $37000.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for BDSX at $37000.0 in Q4 2025, $35000.0 in Q3 2025, and $7000.0 in Q2 2025.